1. Contributors

   EditorialNotes 23 September 2012 Pages: i - i

2. Cost-effectiveness of clopidogrel

   • Christopher P. Cannon

   Editorial 23 September 2012 Pages: 1 - 3

3. Changing health environment: The challenge to demonstrate cost-effectiveness of new compounds

   • Bengt Jönsson

   Review Article 23 September 2012 Pages: 5 - 10

   

4. The burden of coronary, cerebrovascular and peripheral arterial disease

   • Ameet Bakhai

   Review Article 23 September 2012 Pages: 11 - 18

   

5. The value of clopidogrel versus aspirin in reducing atherothrombotic events: The CAPRIE study

   • Isabelle Durand-Zaleski
   • Michel Bertrand

   Review Article 23 September 2012 Pages: 19 - 27

   

6. The value of clopidogrel in addition to standard therapy in reducing atherothrombotic events

   • William S. Weintraub
   • Bengt Jönsson
   • Michel Bertrand

   Review Article 23 September 2012 Pages: 29 - 41